Phase 1 open-label, multicenter, dose escalation study of mRNA-2416 in patients with relapsed/refractory solid tumor malignancies or lymphoma.

Trial Profile

Phase 1 open-label, multicenter, dose escalation study of mRNA-2416 in patients with relapsed/refractory solid tumor malignancies or lymphoma.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs MRNA-2416 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top